THE ONYCHOMYCOSIS PROBLEM
35 million Americans suffer from onychomycosis and FDA approved products have significant drawbacks. Oral products are associated with systemic side effects and topical products have low cure rates and require a full year of daily dosing.
THE HALLUX SOLUTION
Hallux is investigating a new approach: a subungual-topical gel (HSG) that is administered direct to the nail bed site of infection by a physician in a series of quick and easy in-office treatments.